Company: XAIR
Filing Date: 2025-06-20
Form Type: 10-K
Source: 0001641172-25-015750
Chunk: 550

Company: Beyond Air, Inc.
Filing Date: 2025-06-20
Form: 10-K
Item: Item 1
Chunk 550
---
 developing, acquiring or licensing on an exclusive basis, products that are more effective
or less costly than LungFit® PH or any product candidate that we may develop, or achieve earlier patent protection, certification
or regulatory approval, product commercialization and market penetration than we do. Additionally, technologies developed by our competitors
may render LungFit® PH or our potential product candidates uneconomical or obsolete, and we may not be successful in marketing
LungFit® PH or our product candidates against competitors.

35

We currently have a limited marketing
and sales organization. If we are unable to scale sales and marketing capabilities or enter into agreements with third parties to market
and sell LungFit® PH or our product candidates, we may be unable to generate revenue

Although some of our employees
may have sold other similar products in the past while employed at other companies, we as a company have limited experience selling and
marketing our product candidates and we currently have a nascent marketing and sales organization. To successfully commercialize LungFit®
PH or any other products that may result from our development programs, we will need to further develop these capabilities, either on
our own or with others. We continue to refine our commercialization efforts for LungFit® PH and intend to establish a more
complete sales and marketing organization with technical expertise to potentially reach all U.S. hospitals using or capable of using NO.
This will be an expensive, difficult and time-consuming endeavor. Any failure or delay in the development of our internal sales, marketing
and distribution capabilities would adversely impact the commercialization of our products.

Further, given our limited experience
in marketing and selling medical device products, our estimate of the size of the required sales force may be materially more or less
than the size of the sales force actually required to effectively commercialize LungFit® PH and our product candidates.
As such, we may be required to hire substantially more sales representatives to adequately support the commercialization of LungFit®
PH and our product candidates, or we may incur excess costs as a result of hiring more sales representatives than necessary. With respect
to certain geographical markets, we may enter into collaborations with other entities to utilize their local marketing and distribution
capabilities, but we may be unable to enter into such agreements on favorable terms, if at all. If our future collaborators do not commit
sufficient resources to commercialize our future products, if any, and we are unable to develop the necessary marketing capabilities on
our own, we will be unable to generate sufficient product revenue to